Low-dose radiation therapy is linked with improved progression-free survival in patients with advanced Hodgkin lymphoma (HL), according to a study involving 90 individuals. This is the case even in those who experience complete metabolic response after adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Participants had stage III-IV HL and were treated with either chemotherapy alone (n= 46) or combination therapy (n=44) between 1992 and 2012. Chemo regimen was mainly ABVD or a hybrid of it. Investigators looked at outcomes in those who achieved complete metabolic response. Among the results:
- 88% of patients receiving combo therapy experienced 5-year progression-free survival, vs 65% of those who were given chemo alone.
- Overall survival rates were 97% and 78%, respectively.
- Patients <45 years of age and those receiving combination regimens were more likely to experience improved progression-free survival.
- Secondary malignancies were similar in both groups.
- Cardiac events occurred a bit more often in patients receiving combo regimens.
Song E, Torok J, Wu Y, et al. Consolidation radiation therapy for advanced Hodgkin lymphoma in complete metabolic response by PET-CT or gallium. [Published online ahead of print December 29, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.12.007.
This Week's Must Reads
Androgen Deprivation Therapy & Risk of Depression, Cancer; ePub 2019 Feb 12; Deka, Rose, et al
QOL in Patients with Low-Risk PC Treated with HRT, JAMA Oncol; ePub 2019 Feb 14; Bruner, et al
Hospital Competition & Prostate Cancer Outcomes, Cancer; ePub 2019 Feb 1; Aggarwal, et al
Insurance Status & Stage of Prostate Ca Diagnosis, Cancer Epidemiol; 2019 Apr; Ramirez, Morano, et al
Agent Orange Exposure & Prostate Ca Outcomes, J Urol; ePub 2019 Jan 8; Etheridge, et al